Other Events ·
Genprex, Inc. announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent…
GNPXGenprex, Inc.
Genprex, Inc. announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for treating lung cancer. This patent expands on existing patents granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, and other regions. Genprex, Inc. is a biotechnology company developing gene therapy products for oncology and diabetes.